[ET Net News Agency, 16 June 2025] Nomura raised the target price for CSPC Pharma
(01093) to HKD10.22 from HKD8.02 and maintained the "buy" rating.
The research house said it lifts FY25F/26F revenue forecasts by 2.5%/6.4% and earnings
estimates by 20.3%/24.5%, respectively. (rc)